BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 28710407)

  • 1. Role of insulin receptor substrates in the progression of hepatocellular carcinoma.
    Sakurai Y; Kubota N; Takamoto I; Obata A; Iwamoto M; Hayashi T; Aihara M; Kubota T; Nishihara H; Kadowaki T
    Sci Rep; 2017 Jul; 7(1):5387. PubMed ID: 28710407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
    Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
    Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling.
    Wang Y; Hu C; Cheng J; Chen B; Ke Q; Lv Z; Wu J; Zhou Y
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1255-60. PubMed ID: 24690171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.
    Nayeb-Hashemi H; Desai A; Demchev V; Bronson RT; Hornick JL; Cohen DE; Ukomadu C
    Biochem Biophys Res Commun; 2015 Sep; 465(2):167-73. PubMed ID: 26225745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
    Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
    Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
    Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
    Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
    Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promotion of growth factor signaling as a critical function of β-catenin during HCC progression.
    Kim E; Lisby A; Ma C; Lo N; Ehmer U; Hayer KE; Furth EE; Viatour P
    Nat Commun; 2019 Apr; 10(1):1909. PubMed ID: 31015417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin.
    Li J; Dai X; Zhang H; Zhang W; Sun S; Gao T; Kou Z; Yu H; Guo Y; Du L; Jiang S; Zhang J; Zhou Y
    Oncotarget; 2015 Oct; 6(30):29196-208. PubMed ID: 26470691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.
    Zhang Q; Bai X; Chen W; Ma T; Hu Q; Liang C; Xie S; Chen C; Hu L; Xu S; Liang T
    Carcinogenesis; 2013 May; 34(5):962-73. PubMed ID: 23358852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.
    Helms TH; Mullins RD; Thomas-Ahner JM; Kulp SK; Campbell MJ; Lucas F; Schmidt N; LeMoine DM; Getaneh S; Xie Z; Phelps MA; Clinton SK; Coss CC
    Sci Rep; 2021 Feb; 11(1):3646. PubMed ID: 33574348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.
    Law PT; Ching AK; Chan AW; Wong QW; Wong CK; To KF; Wong N
    Carcinogenesis; 2012 Jun; 33(6):1134-41. PubMed ID: 22431718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6.
    Lai KKY; Kweon SM; Chi F; Hwang E; Kabe Y; Higashiyama R; Qin L; Yan R; Wu RP; Lai K; Fujii N; French S; Xu J; Wang JY; Murali R; Mishra L; Lee JS; Ntambi JM; Tsukamoto H
    Gastroenterology; 2017 May; 152(6):1477-1491. PubMed ID: 28143772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
    Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
    J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
    Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
    Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.